ArticleRomanian journal of ophthalmology
Conjunctival lymphoma: case report.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report the diagnosis and therapeutic approach in the case of a patient with conjunctival lymphoma. Case presentation: A 54-year-old caucasian female presented to the hospital with a painless conjunctival mass in the right eye of at least three months duration. The ophthalmological examination showed a "salmon patch" conjunctival lesion in the inferior fornix. An incisional biopsy of the conjunctival lesion was performed, and the histopathological examination confirmed the diagnosis of extranodal marginal zone B-cell conjunctival lymphoma. The CT scan showed no systemic involvement. It was decided to start radiotherapy with brachytherapy. Discussion: Conjunctival lymphoma is a rare ocular malignancy arising from polyclonal proliferation of lymphocytes. The most common subtype is extranodal marginal zone B-cell lymphoma (EMZL), followed by diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and T-cell lymphoma (TL). Clinical manifestations are non-specific; they usually present as a unilateral or bilateral painless, salmon-pink conjunctival lesion, often without systemic symptoms. Definite diagnosis requires conjunctival biopsy and relies on histopathology and immunohistochemistry, with molecular profiling playing an increasing role in risk stratification. Treatment strategies include: radiotherapy, immunotherapy (Interferon-α2b, Rituximab), chemotherapy, and antibiotherapy. Prognosis is generally favorable, with high survival rates, especially in localized cases. Conclusions: Conjunctival lymphoma can be easily overlooked during a routine examination; therefore, a thorough clinical evaluation, advanced imaging, histopathological, and immunohistochemical analysis are essential for appropriate management. Systemic staging and an interdisciplinary approach involving ophthalmology, medical oncology, and radiation oncology are necessary for optimal treatment planning and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.